Latest News for: tcr
Edit
Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody ...
Business Wire 18 Mar 2026
Edit
Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer
Pharmiweb 18 Mar 2026
Crossbow is developing a broad portfolio of novel T-cell engager (TCE) therapies that potently target peptide human leukocyte antigen (pHLA) on cancer cells, using antibodies that mimic T-cell receptors (TCR-mimetics).
Edit
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours (Zelluna ASA)
Public Technologies 17 Mar 2026
Edit
Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours (Zelluna ASA)
Public Technologies 17 Mar 2026
Edit
Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering
Nasdaq Globe Newswire 09 Mar 2026
... machine learning to T cell receptor (TCR) discovery and engineering.
Edit
Clifford Chance advises 3i Infrastructure plc on the sale of TCR to GIP (Clifford Chance LLP)
Public Technologies 09 Mar 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 130031659) .
Edit
Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering (Zelluna ASA)
Public Technologies 09 Mar 2026
Edit
TCR Therapy Clinical Trial Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market ...
GetNews 06 Mar 2026
Inactive Products TCR-Therapy Key Companies TCR-Therapy Key Products TCR-Therapy- Unmet Needs TCR-Therapy- Market Drivers and Barriers TCR-Therapy- Future Perspectives and Conclusion TCR-Therapy Analyst Views TCR-Therapy Key Companies Appendix.
Edit
Fapon Biopharma to Present Next-Generation CD3/TCR VHH TCE Platform at 19th Annual European Life Sciences CEO Forum
PR Newswire 04 Mar 2026
Edit
Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours
Nasdaq Globe Newswire 16 Dec 2025
Oslo, Norway, 16 December 2025– Zelluna (OSE ... .
Edit
EMCCA: TCR delivery plan 2024 to 2025 (DFT - UK Department for Transport)
Public Technologies 16 Dec 2025
). This document provides a progress update on the East Midlands Combined County Authority's () Transport for City Regions () settlements delivery plan between 2024 and 2025 ... Attachments Original document Permalink. Disclaimer.
- 1